ANA by ELISA at Biotech Lahore Lab

ANA by ELISA at Biotech Lahore Lab

The Antinuclear Antibody (ANA) by ELISA test at Biotech Lahore Lab in Lahore, Pakistan, is a highly specialized, evidence-based laboratory investigation used to screen for autoimmune disorders. This diagnostic test detects the presence of autoantibodies in the blood serum that mistakenly target the nucleus of the patient’s own healthy cells. By utilizing Enzyme-Linked Immunosorbent Assay (ELISA) technology, the laboratory provides a quantitative and highly sensitive assessment of these antibodies. This plays a critical role in the clinical evaluation of systemic autoimmune diseases, helping rheumatologists and physicians differentiate between autoimmune pathologies and other chronic inflammatory conditions.

The ELISA methodology works by binding target antinuclear antibodies present in the patient’s blood sample to specific nuclear antigens pre-coated on a microtiter plate. When the patient’s serum is added, any ANA present will bind to these antigens. A subsequent enzyme-linked conjugate is introduced, followed by a chromogenic substrate that produces a color change proportional to the concentration of antinuclear antibodies. This advanced diagnostic technology ensures high sensitivity and reproducibility, making it an invaluable tool for evaluating systemic lupus erythematosus (SLE), Sjögren’s syndrome, scleroderma, and mixed connective tissue disease. Accurate detection of these autoantibodies is crucial for establishing an early diagnosis, preventing irreversible organ damage, and guiding targeted therapeutic interventions.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest accuracy of your ANA by ELISA test at Biotech Lahore Lab, patients are advised to follow these preparation guidelines:

• Fasting Requirements: Routine fasting is generally not required for an ANA ELISA test. Patients can eat and drink normally unless instructed otherwise by their physician or if concurrent tests require fasting.
• Medication History: Inform your prescribing physician and the laboratory staff of all medications, supplements, and herbal remedies you are currently taking. Certain drugs, such as hydralazine, procainamide, isoniazid, and some anti-seizure medications, can induce drug-induced lupus and alter test results.
• Hydration: Ensure adequate hydration before the blood draw, as this makes the veins more accessible and facilitates a smoother venipuncture process.
• Stress Management: Minimize physical exertion and acute stress immediately prior to the test, as extreme physiological stress can occasionally influence immune markers.

During the Procedure

The collection of the blood sample for the ANA by ELISA test is a standard, minimally invasive outpatient procedure conducted by experienced phlebotomists at Biotech Lahore Lab:

• Patient Positioning: The patient is comfortably seated in a specialized phlebotomy chair, and the arm is extended and supported.
• Site Selection and Sanitization: The phlebotomist identifies a suitable vein, typically the median cubital vein in the antecubital fossa. The skin over the selected vein is thoroughly sanitized using an antiseptic swab to prevent contamination.
• Venipuncture: A sterile, single-use needle is gently inserted into the vein. A vacuum collection tube (typically a gold-top serum separator tube or red-top tube) is attached to collect the required volume of blood.
• Duration and Sensation: The actual blood collection process takes less than two minutes. Patients may feel a brief, mild prick or pinch as the needle enters the skin.
• Post-Collection Care: Once the sample is collected, the needle is withdrawn, and gentle pressure is applied to the puncture site with a sterile cotton ball or gauze pad to stop any bleeding. A small adhesive bandage is then applied.
• Sample Processing: The collected blood sample is allowed to clot, centrifuged to separate the serum, and then processed using state-of-the-art ELISA microplate readers under strict quality control protocols.

When is an ANA by ELISA Performed?

Suspected Systemic Lupus Erythematosus (SLE)

Physicians frequently order the ANA by ELISA test when a patient exhibits clinical signs suggestive of Systemic Lupus Erythematosus. SLE is a chronic, multisystem autoimmune disease that can affect the joints, skin, kidneys, blood cells, brain, heart, and lungs. The high sensitivity of the ELISA method makes it an exceptional screening tool; a negative result strongly rules out active SLE, while a positive result prompts further specific autoantibody testing to confirm the diagnosis.

Evaluation of Sjögren’s Syndrome

Sjögren’s syndrome is an autoimmune condition characterized by the destruction of exocrine glands, primarily leading to severe dryness of the eyes (xerophthalmia) and mouth (xerostomia). When patients present with persistent dry eyes, dry mouth, joint pain, and chronic fatigue, clinicians utilize the ANA by ELISA test as an initial diagnostic step to identify underlying systemic autoimmune activity before proceeding to more specific SSA (Ro) and SSB (La) antibody testing.

Investigation of Systemic Sclerosis (Scleroderma)

Systemic sclerosis is a rare autoimmune disease involving abnormal growth of connective tissue, leading to diffuse skin thickening, vascular abnormalities, and visceral organ involvement. Clinicians request an ANA test when patients present with Raynaud’s phenomenon (color changes in fingers in response to cold), skin tightening, or unexplained esophageal dysfunction, as specific ANA patterns and titers are highly associated with different clinical subsets of scleroderma.

Assessment of Mixed Connective Tissue Disease (MCTD)

Mixed Connective Tissue Disease is an overlap syndrome featuring clinical characteristics of SLE, systemic sclerosis, and polymyositis. Because the clinical presentation can be highly variable and mimic other diseases, the ANA by ELISA test serves as an essential initial laboratory investigation. A positive ANA result, followed by high titers of anti-U1-RNP antibodies, helps clinicians confidently diagnose MCTD and initiate appropriate immunosuppressive therapy.

Unexplained Chronic Joint Pain and Systemic Inflammation

When patients present with persistent, unexplained joint pain, muscle weakness, low-grade fever, fatigue, and elevated inflammatory markers (such as ESR or CRP) without a clear infectious or mechanical cause, an ANA by ELISA is indicated. This test helps determine whether the underlying cause is an autoimmune process, allowing primary care physicians to make timely referrals to rheumatologists for specialized management.

What Does an ANA by ELISA Detect?

The ANA by ELISA test is designed to detect and semi-quantitatively measure antibodies directed against various nuclear and cytoplasmic antigens, including but not limited to:

• Double-stranded DNA (dsDNA) antibodies
• Single-stranded DNA (ssDNA) antibodies
• Histones and nucleosomes
• Sjögren’s Syndrome A (SSA/Ro) and B (SSB/La) antigens
• Smith (Sm) antigen
• Ribonucleoprotein (RNP) complexes
• Scl-70 (topoisomerase I) antigen
• Centromere proteins
• Jo-1 (histidyl-tRNA synthetase) antigen
• Ribosomal P proteins
• Nucleolar antigens
• PM-Scl antigens
• Mi-2 antigens
• Fibrillarin
• RNA polymerase III
• PCNA (Proliferating Cell Nuclear Antigen)
• U1-RNP complex
• Ku antigen
• Ro-52 antigen
• Other soluble nuclear and cytoplasmic macromolecular complexes

Turnaround Time and Report Access at Biotech Lahore Lab

At Biotech Lahore Lab, we understand that timely diagnostic results are essential for clinical decision-making and patient peace of mind. The ANA by ELISA test is performed by skilled laboratory technologists utilizing automated ELISA platforms to ensure rapid and accurate processing. Typically, the official diagnostic report is completed and verified by a Consultant Pathologist within 24 to 48 hours of sample collection. Patients and referring physicians can conveniently access, view, and download the digital reports online through the secure Biotech Lahore Lab web portal or via dedicated mobile services, eliminating the need for unnecessary travel back to the facility.

ANA by ELISA Findings Overview

Parameter Evaluated	Normal Findings	Possible Abnormal Findings
ANA ELISA Index Value	Negative (typically < 1.0 Units)	Positive (≥ 1.0 Units) indicating presence of antinuclear antibodies
Anti-dsDNA Association	Absent	Highly specific for Systemic Lupus Erythematosus (SLE)
Anti-Sm Association	Absent	Diagnostic marker for Systemic Lupus Erythematosus (SLE)
Anti-SSA (Ro) / Anti-SSB (La)	Absent	Strongly associated with Sjögren’s Syndrome and Neonatal Lupus
Anti-Scl-70 / Anti-Centromere	Absent	Associated with Diffuse and Limited Systemic Sclerosis (Scleroderma)
Anti-U1-RNP	Absent	Key diagnostic marker for Mixed Connective Tissue Disease (MCTD)
Anti-Jo-1	Absent	Associated with Polymyositis, Dermatomyositis, and Antisynthetase Syndrome

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Biotech Lahore Lab for ANA by ELISA?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists and technologists specializing in clinical immunology.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the testing process.
• Quality Diagnostic Services: Biotech Lahore Lab adheres to stringent internal and external quality control measures for highly reproducible results.
• Professional Reporting: Comprehensive reports are verified by consultant pathologists to assist clinicians in accurate diagnosis.
• Modern Diagnostic Approach: We utilize advanced ELISA technology and automated platforms to minimize human error.
• Comfortable Environment: Our collection centers in Lahore are designed to provide a clean, hygienic, and stress-free experience.
• Convenient Location: Easily accessible diagnostic facilities situated across Lahore, Pakistan, for patient convenience.
• Commitment to Accurate Diagnosis: We are dedicated to providing precise, evidence-based diagnostic insights that support effective patient management.